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Indeed, in the creation of the heavens and the earth, and the alteration of the night 
and day are signs for those of understanding. 
[3:190] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my beloved family 
  
  
ABSTRACT 
The production of blood cells (hematopoiesis), where the hematopoietic stem cell 
(HSC) is the cell of origin of all blood cells, is regulated by a complex network of 
intrinsic and extrinsic signals. Dysregulation of hematopoiesis, including somatic 
heterozygous mutations, cytogenetic aberrations, or epigenetic aberrations, are 
found in hematological malignancies. Advances in the technical field have lead to 
identification of many genetic and epigenetic alterations in myeloid malignancies. 
However, their exact role in disease pathogenesis and prognosis remains unclear. 
The main purpose of this thesis was to explore the role of epigenetic alterations in 
the myeloid malignancies systemic mastocytosis (SM), the myelodysplastic 
syndromes (MDS), and acute myeloid leukemia (AML). 
In study I, we investigated the overall effect on the epigenome caused by Azacitidine 
in primary MDS bone marrow CD34+ cells. We observed an increase in genes 
important for the immune system, ERVs, however with no clear correlation with the 
changes in the epigenome. 
In study II, four different HDACi were found to dose dependently kill KIT D816V 
mutated mast cells. Primary patient mast cells were selectively targeted compared to 
healthy mast cells, and the more aggressive disease, the more sensitive to HDACi 
mediated killing. 
In study III, we examined the epigenetic effects of Selenium compounds in AML cell 
line K562 as well as primary patient AML cells, and found that MSA treatment 
affected the adhesion capacity of AML cells, which may implicate MSA as a 
complement to chemotherapy to better target leukemic cells in the bone marrow 
niche. 
In study IV, we further investigated the mechanism of action of the findings in study 
II, delineating the effects of HDACi treatment on mast cell epigenome and 
transcriptome. We demonstrate a direct effect of HDACi on KIT as well as KIT 
downstream signaling in D816V KIT mutated cells. 
In conclusion, this thesis provides insight of the mechanism of action of 
epigenetically active drugs used in the clinic today, findings that may have direct 
consequences for improved treatment strategies in myeloid malignancies. 
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1 INTRODUCTION 
1.1 EPIGENETICS  
Every cell in the human body has identical genetic information, yet a variety of cell 
types with different phenotype and function are produced. Conrad Waddington first 
introduced the term “epigenetics” in 1942, in a model describing the influence of 
different developmental stimuli on the inheritance of acquired phenotypes (Noble 
2015). In this model, the developmental landscape contains a series of decisions 
that he referred to as “valleys” and “forks”. The cell is represented as a ball rolling 
down this developmental landscape and will be “canalized” to a well-defined valley, 
which represents a mature cell state.  With this model Waddington described 
epigenetics as the mechanism that gives rise to multiple cellular phenotypes from 
the same genotype during development (Felsenfeld 2014, Noble 2015). 
With the increasing knowledge in molecular biology during the past decades, the 
definition of epigenetics has been modified to a great extent. In 1996, Riggs and 
Porter laid forward a more modern description of epigenetics, where they proposed a 
model including stable changes in gene function during cell division, that cannot be 
explained by changes in the genetic information (Hurd 2010). 
The term epigenetics has been further modified in a model describing the specific 
mechanisms of epigenetic regulation. In this model (Figure 1) three categories of 
signals that lead to the establishment of a stably heritable epigenetic state are 
introduced as: “epigenator”, describing the environment which triggers an 
intracellular pathway; “epigenetic initiator signal”, which responds to the 
environmental stimuli and localizes the epigenetic environment; and a signal that 
maintains the heritable changes defined as “epigenetic maintainer signal” (Berger, 
Kouzarides et al. 2009). 
The term epigenetics is henceforth referring to cellular memories of chromatin 
states, which are stable during the lifespan of an organism, and are crucial for a 
stable maintenance of cell type specific gene expression patterns and normal 
development (Felsenfeld 2014). 
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Figure 1. Schematic illustration of heritable changes in a cell. Extracellular stimuli such 
as differentiation signals or temperature changes that trigger an intracellular signaling 
cascade are referred to as epigenator. The epigenetic initiators receive the signal, which 
localizes the signal to the chromatin, through DNA binding factors and non-coding RNAs. 
The signal is maintained and transmitted to coming generations by the “epigenetic 
maintainers”, by histone and DNA modifiers. Figure adapted with permission from publisher 
(Berger, Kouzarides et al. 2009). 
 
1.1.1 Chromatin  
The eukaryotic cell consists of approximately two meters of DNA, assembled into the 
nuclei in the form of a compacted spherical structure with the diameter of 10 µm. 
This macromolecular complex of DNA wrapped around a protein nucleosome in a 
compact structure, is referred to as chromatin (Kornberg 1977). By organizing the 
chromatin in structures of different degree of compaction, several specialized 
chromatin forms are constructed. These can be subdivided into mainly two structural 
states; heterochromatin, a highly condensed chromatin state, which mainly contains 
inactive genes and gene-poor regions and replicates in late S-phase; and 
euchromatin, which is less condensed and contains mostly active genes and 
replicates in early S-phase (Kornberg and Lorch 1992) 
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In order for genetic information to be expressed in a controlled way, one function of 
the chromatin is to regulate DNA accessibility for the many factors involved in gene 
regulation, such as transcription factors, repair- and replication factors.   
1.1.2 The nucleosome and histones  
The nucleosome consists of an octameric histone structure with 146 bp of DNA 
wrapped around it. Two copies of each of the core histones, H2A, H2B, H3 and H4, 
form the octameric structure. The core histones assemble in H2A-H2B and H3-H4 
dimers, forming the octameric structure with two H3-H4 dimers in the center and two 
flanking H2A-H2B dimers above and below (Kornberg and Lorch 1992, Grimes, 
Babcock et al. 2004).   
Histone proteins are positively charged, due to several positively charged amino acid 
residues in backbone (lysine, arginine), which will create a tight structure with the 
negatively charged DNA based on electrostatic interactions. Linker DNA and the 
linker histone H1 further connect each nucleosome into a compact structure, by 
changing the entry and exit angle of DNA into each nucleosome. Further twisting 
and supercoiling compacts the chromatin into a highly condensed form. The stability 
of the nucleosome is dependent on many factors, such as modifications on the 
underlying DNA and histone that may disrupt the tight structure. 
The core and linker histones, referred to as canonical histones, are synthesized only 
in the S phase of the cell cycle, and their deposition into the chromatin takes place in 
a DNA replication-dependent manner (Kurat, Recht et al. 2014). The mRNA of the 
canonical histones lack introns and contain a specialized stem-loop structure at their 
3′ end instead of the polyadenylation tail (Marzluff 2005). 
1.1.2.1 Histone variants  
In contrast to the canonical histones, there are histones that are synthesized and in-
corporated into the chromatin in a replication-independent manner through specific 
chaperones and ATP-dependent chromatin-remodeling factors (Talbert and Henikoff 
2017). These are referred to as replacements histones or histone variants, which are 
produced via alternative splicing.  
The histone variants are highly conserved between species, indicating an important 
functionality (Talbert, Ahmad et al. 2012). 
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Replacement of the canonical histones with histone variants modifies the 
arrangement and allocation of nucleosomes as well as DNA-binding proteins. This in 
turn will change the nucleosome properties and the communication with chromatin 
remodeler and modifiers (Talbert and Henikoff 2017). 
 Eight histone variants of H2A (H2A.X, H2A.Z.1, H2A.Z.2.1, H2A.Z.2.2, H2A.Bbd, 
macroH2A1.1, macroH2A1.2 and macroH2A2), two variants of H2B (H2BWT, 
H2B1A) and six variants of H3 (H3.3, CENP-A, H3.1T, H3.5, H3.X and H3.Y) have 
been characterized in human somatic cells (Talbert, Ahmad et al. 2012). No histone 
variants for H4 have yet been discovered in higher eukaryotes (Buschbeck and Hake 
2017). A histone variant may be associated with a specific chromatin state, for 
example the H3 variant H3.3 is associated with transcriptionally active chromatin, 
and the other H3 variant CENP-A is associated with centromeric chromatin leading 
to a repressed chromatin state (Talbert and Henikoff 2017). The histone variant 
H2A.Z however, may be linked to both active and repressive chromatin state, 
depending on its posttranslational modifications. In active gene promoter regions, 
H2A.Z is acetylated, and in heterochromatin, H2A.Z is ubiquitinylated (Monteiro, 
Baptista et al. 2014). Phosphorylated H2AX (γ-H2AX) is linked with DNA double 
strand damage (Pouliliou and Koukourakis 2014). 
1.1.3 Histone posttranslational modifications  
Histones can be chemically modified on amino acid side chains, at the N-terminal 
protruding histone tail, by posttranslational modifications (PTM). These may promote 
either an active or repressive chromatin state. X-ray crystal structure studies have 
revealed that the histone N-terminal tails are stretching to adjacent nucleosomes, 
indicating that modifications on these tails may affect the overall chromatin structure 
and function (Luger, Mader et al. 1997). 
The Histone PTMs are diverse and include at least 15 different modifications; 
acetylation of lysine; methylation of lysine and arginine; phosphorylation of threonine 
and tyrosine; ubiquitinylation, sumoylation, ADPribosylation and citrullination of 
methyl-arginine residues. Along which histone acetylation, methylation and 
phosphorylation are the most well described PTMs (Bannister and Kouzarides 
2011). 
Upon the addition of an acetyl group on the lysine side chain, the positive charge of 
lysine becomes neutral, which leads to decreased electrostatic interaction with the 
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bound DNA and less compaction of the chromatin. As a consequence, highly 
acetylated sites tend to promote a more open chromatin state. The dynamics of 
histone acetylation is regulated by two categories of enzymes that have the 
opposing mode of action; acetyl groups are added by lysine- and histone 
acetyltransferases (KATs/HATs) and removed by histone deacetylases (HDACs) 
(Marmorstein and Zhou 2014) (Figure 2). 
Histone acetylation is a mark of active chromatin, and in transcribed genes, H3K9ac 
is found enriched in transcription start sites (TSS), H3K12ac is enriched in the gene 
body and H3K27ac and H3K122ac in enhancer regions (Wang, Zang et al. 2008, 
Tang, An et al. 2014). 
Depending on the cellular localization of the HATs they can be further divided into 
two classes of groups, cytoplasmic HATs (acetylates free histones) and nuclear 
HATs (acetylates histones bound to the chromatin) (Parthun 2007, Bannister and 
Kouzarides 2011). There are three main groups of HATs that are based on the 
amino acid side chain sequence and structural similarities; these are GNAT, MYST 
and p300/CREB-binding protein families.  
The acetyl groups are removed from the histone through the action of HDACs, which 
are divided into 4 main classes based on their amino acid side chains (de Ruijter, 
van Gennip et al. 2003). The members of class I, II and IV HDACs share common 
catalytic activity, in contrast the members of class III HDACs require NAD+ as a 
cofactor for the enzymatic reaction and are also referred to as sirtuins. The different 
HDACs have specific roles in differentiation and development; HDAC1 is involved in 
embryonic (ES) cell differentiation, HDAC3 is involved in neuronal differentiation and 
HDAC2 is involved in oligodendrocyte differentiation (Castelo-Branco, Lilja et al. 
2014). 
The amino acid side chains of histones can also be subjected to methylation, by the 
addition of a methyl group. In contrast to the acetylation, methylation doesn’t change 
the positive charge of the histones. Methylation can however take place in the form 
of mono-, di- or tri-methylation (depending on the number of added methyl groups) 
on lysine residues, and mono- or di-methylation symmetrically or asymmetrically on 
arginine residues, which adds another level of complexity (Bannister and Kouzarides 
2011). 
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Figure 2: Schematic illustration of interplay between epigenetic maintainers. Activation 
or repression is controlled through the interplay between writers (histone lysine acetyl 
transferases (HAT/KAT), histone lysine methyltransferases (KMT) and protein arginine 
methyl transferases (PRMT)), readers (bromodomain, chromodomain, tudordomain) and 
erasers (histone deacetylases (HDAC), lysine demethylases (KMD) and phosphatases). 
Figure adapted from publisher with permission (Ungerstedt 2018).  
 
The enzymes responsible for the histone lysine and arginine methylation are referred 
to as histone lysine methyltransferases (KMTs) and histone protein arginine 
methyltransferases (PRMTs). These enzymes catalyze the transfer of a methyl 
group from S-adenosylmethionine (SAM) to respective amino acid group side chain 
(Blanc and Richard 2017). Similar to histone acetylation there is an active turnover 
mechanism for histone methylation, which is performed via specific demethylation 
enzymes with different substrate specificity depending on associated cofactors 
(Blanc and Richard 2017, Wesche, Kuhn et al. 2017). 
Histone methylation can either be associated with a repressed or active chromatin 
state depending on the context that they are enriched in, for example; methylation on 
lysines H3K4, H3K36 and H3K79 are associated with transcriptional activation; while 
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methylation on lysines H3K9, H3K27 and H4K20 are associated with a 
transcriptionally repressed state (Bannister and Kouzarides 2005).  
The different modifications within each group also diverge in their distribution pattern; 
H3K4me3 is distributed as a sharp peak around TSS of active genes, compared to 
H3K36me3 which is enriched throughout the transcribed sites of the active genes 
(Bannister and Kouzarides 2005). The PTMs linked to heterochromatin formation 
also show similar difference in enrichment pattern; H3K9me3 is highly enriched in 
pericentric heterochromatin, while H3K27me3 is enriched in the inactive X-
chromosome heterochromatin) (Bernstein, Mikkelsen et al. 2006). In the promoter 
regions of developmentally regulated genes in ES cells there are both active 
(H3K4me3) and repressive (H3K27me3) histone marks, so called “bivalent 
domains”, that seem to promote transcription competence for those genes 
(Bernstein, Mikkelsen et al. 2006, Li, Wan et al. 2018). 
Different enzymes with specialized tasks facilitate the dynamics of epigenetic 
regulation. The positions to be modified are recognized by the writers, which are site-
specific enzymes such as HATs, KMTs and PRMTs. Each modification has to be 
read and translated into specific function, which is performed by the interaction with 
enzymes called the readers, such as proteins with bromodomain, chromodomain, 
and tudordomain. Specialized enzymes mediate removal of each modification, 
referred as erasers, such as HDACs, KMTs and various phosphatases (Figure 2) 
(Falkenberg and Johnstone 2014, Feinberg, Koldobskiy et al. 2016). 
1.1.4 DNA methylation  
DNA can be subjected to chemical modification by the covalent addition of a methyl 
group, from S-adenosylmethionine on 5’ position of cytosine residues, giving rise to 
5mC. There are three DNA methyltransferase (DNMT) enzymes that are responsible 
for establishing and maintaining DNA methylation; DNMT1, DNMT3A and DNMT3B 
during cell divisions (Okano, Bell et al. 1999). De novo methylation is performed by 
DNMT3A and DNMT3B, and maintained during S phase by DNMT1 that methylates 
the newly synthesized hemimethylated DNA (Okano, Bell et al. 1999). However, it 
has been demonstrated that all three DNMTs are participating in maintaining the 
DNA methylation patterns during cell division (Liang, Chan et al. 2002, Jones and 
Liang 2009).  
 8 
Regions with high density of cytosine and guanine bases (CpGs) also referred to as 
CpG islands (CGIs). CGIs that are located in promoter sites are often unmethylated 
in somatic cells (Lynch, Smith et al. 2012). In contrast regions outside of the CGIs 
are often methylated, in many cancer cells these regions are hypomethylated 
(Ehrlich 2009, Wild and Flanagan 2010). Hypermethylation of promoter CGIs is 
frequently seen in many cancers, often linked with silencing of tumor suppressor 
genes (Christiansen, Andersen et al. 2003, Agrawal, Hofmann et al. 2007). Genes 
that should be maintained silenced during a long period of time under normal 
conditions, for example genes in the inactive X-chromosome, have heavily 
methylated promoter CGIs (Tanay, O'Donnell et al. 2007). 
Promoter DNA methylation is associated with repressed transcription. The 
consequences of gene body DNA methylation are unclear, however have suggested 
being associated with active transcription ((Illingworth, Gruenewald-Schneider et al. 
2010, Maunakea, Nagarajan et al. 2010). 
DNA demethylation occurs via either passive mechanism (replication dependent) or 
two active mechanisms, (1) deamination via the activation-induced cytosine 
deaminase (AID) or through the apolipoprotein B mRNA-editing enzyme (APOBEC) 
and (2) oxidation of the 5mC through ten eleven translocation (TET) dioxygenases 
(Figure 3). The deamination process results in converts the 5mC to uracil leading to 
a T-G mismatch that is then cleaved by the thymine-DNA glycosylase (TDG), 
between the 5mC and the deoxyribose ring which creates an abasic site and leads 
to a base excision repair (BER) reaction that converts the 5mC to unmethylated 
cytosine (5C) (Figure 3) (Rai, Huggins et al. 2008, Zhu 2009). 
The other mechanism through oxidation via the TET enzymes (TET1-3) is mediated 
via an oxidation of 5-methyl cytosine (5mC) to form 5- hydroxymethylcytosine 
(5hmC). This mechanism is a stepwise oxidation process that converts 5hmC to 5-
formylcytosine (5fC) and further to carboxylcytosine (5caC), which is excised by 
TDG and eventually to unmethylated cytosine via the BER reaction (He, Li et al. 
2011, Ito, Shen et al. 2011) (Figure 3). 
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Figure 3: Schematic illustration of DNA methylation and demethylation mechanisms.  
DNA demethylation can either take place through passive or active mechanisms. Figure 
illustrated by Hani Abdulkadir Ali. 
 
1.1.5 Crosstalk between chromatin modifiers  
The crosstalk between DNA methylation and histone modifications is a dynamic 
process, utilizing specific proteins and enzymes, and we are only just beginning to 
understand these complex interactions. Crosstalk between different epigenetic 
modalities are likely crucial for maintaining the cellular state during cell division and 
development.  
 Regions with methylated CpGs attract proteins that contain methyl binding groups 
(MBD), such as MECP2 and MBD1-4, that will compact the chromatin and reinforce 
the repression of transcription through the recruitment of transcriptional silencing 
machinery (Baubec, Ivanek et al. 2013), including recruitment of HDACs but also the 
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repressive histone mark H3K9me3, which will compact the chromatin further (Wade 
and Wolffe 2001). Studies of NANOG promoter and OCT4 enhancer repression 
during differentiation clearly demonstrate an addition of DNA methylation that 
stabilizes an already repressed chromatin state (You, Kelly et al. 2011). 
On the other hand, unmethylated DNA sites are recognized by proteins that contain 
the CXXC-domain, such as the CXXC finger protein 1 (CFP1), histone methylases 
(MLL1 and MLL2) and histone demethylases KDM2A and KDM2B) (You, Kelly et al. 
2011, Long, Blackledge et al. 2013).  The CFP1 protein is directing H3K4methylation 
to promoters through the recruitment of H3K4 methyltransferases.  
The three DNMTs all have the ATRX-DNMT3-DNMT3L (ADD) domain that binds to 
unmethylated H3K4, which is associated with transcriptional inactivation (Ooi, Qiu et 
al. 2007, Zhang, Jurkowska et al. 2010).   
The crosstalk between H3K4 methylation and DNA methylation is important for the 
establishment of DNA methylation patterns during embryonic development, which is 
taking place through the action of H3K4 demethylases ((Ciccone, Su et al. 2009, 
Wang, Hevi et al. 2009). The histone variant H2A.Z has also been involved in 
crosstalk with DNA methylation, and H2A.Z is strongly inversely correlated to DNA 
methylation in actively transcribed genes (Zilberman, Coleman-Derr et al. 2008, 
Conerly, Teves et al. 2010).  
The H3K9 methyltransferases facilitate DNA methylation through the recruitment of 
DNMTs (Meissner, Mikkelsen et al. 2008). The repressive histone mark H3K27me3 
has also been linked to DNA methylation, as promoter CGIs Another repressive 
histone mark that has been linked to DNA methylation crosstalk is H3K27me3, 
where promoter CGIs in regions that are enriched with H3K27me3 have a higher 
probability of acquiring DNA methylation during development (Mohn, Weber et al. 
2008). 
1.1.6 Transcription 
The transcriptional regulation of coding genes is a key mechanism in the 
establishment of a cell type specific phenotype. Nuclear RNA polymerases (RNA Pol 
I, RNA Pol II, and RNA Pol III) carry out transcription in eukaryotic cells, where RNA 
Pol I transcribes ribosomal RNA (rRNA) precursors, Pol III transcribes non-coding 
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RNAs and Pol II is involved in the transcription of protein-coding genes to produce 
messenger RNA (mRNA).  
Transcriptional initiation involves assembly of the five general transcription factors 
(GTFs) (TFIIB, TFIID, TFIIE, TFIIF and TFIIH) by Pol II at promoter DNA to form a 
pre-initiation complex (PIC) (Liu, Bushnell et al. 2013). The double stranded DNA is 
transformed to a single strand by the action of TFIIH, Pol II can then interact with the 
open DNA and facilitate the RNA synthesis (Smolle and Workman 2013). The 
TATA-box binding protein (TBP), present in TFIID, initiates transcription at 
promoter sites (Liu, Bushnell et al. 2013). However, promoter initiated Pol II 
transcription is not the only mechanism for transcription of genes. In recent years, 
regions that are distal from the TSS have been described to be associated with 
transcription. These regions are referred to as enhancers or insulators ((Butler and 
Kadonaga 2002), and enhancers can be repressed or themselves enhanced, via 
the action of several transcription factors (TFs). In enhancer region DNA, DNA 
binding proteins are found, and these proteins enable DNA to form loops to the 
target gene promoter (Visel, Blow et al. 2009, Andersson, Gebhard et al. 2014). In 
the pursuit to identify enhancer elements, increased H3K4me1 and H3K27ac 
together with the absence of H3K27me3 are associated with active enhancer 
regions (Pennacchio, Bickmore et al. 2013, Heinz, Romanoski et al. 2015). Bivalent 
enhancers, which are capable of fast activation or repression of target genes, are 
defined by the presence of H3K27me3 and H3K4me1 at low levels together with 
the absence of H3K27ac (Heintzman, Stuart et al. 2007, Visel, Blow et al. 2009).  
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1.2 HEMATOPOIESIS 
Different types of blood cells are responsible for specialized tasks, such as oxygen 
supply, wound healing and protection from pathogens. These mature blood and 
immune cells are produced from the multipotent hematopoietic stem cells (HSCs), in 
the developmental process referred to as hematopoiesis (Jagannathan-Bogdan and 
Zon 2013, Crisan and Dzierzak 2016). The early research of HSCs demonstrated a 
self-renewing multipotent potential of the HSCs; that has the ability to generate 
different lineages determined through both intrinsic and extrinsic factors (Figure 4) 
(Eaves 2015).  
The initial step in the differentiation process requires loss of self-renewal capacity, in 
order to generate progenitor cell stages with a restricted degree of potency.  The 
HSCs give rise to the multipotent hematopoietic progenitor cells (MPPs), which in 
turn generates common myeloid progenitors (CMPs) and common lymphoid 
progenitors (CLPs). The CMPs can further produce granulocyte and macrophage 
progenitors (GMPs) and megakaryocyte and erythrocyte progenitors (MEPs), while 
the CLPs produce progenitors of B, T and NK cells (Kondo, Weissman et al. 1997, 
Akashi, Reya et al. 2000, Manz, Miyamoto et al. 2002). 
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Figure 4: Schematic illustration of hematopoiesis. The differentiation process starts from 
multipotent self-renewable HSCs, which have the capacity to generate committed progenitor 
cells and different mature blood cells. Figure reprinted with permission from the publisher 
(Wikipedia 2018). 
 
1.2.1 Epigenetic regulation of hematopoiesis  
Epigenetic regulation has been proven to be important in hematopoiesis, affecting 
both cellular identity and differentiation (Sharma and Gurudutta 2016). The level of 
DNA methylation affects myeloid and lymphoid lineage commitment, in that a 
reduced DNA methylation by reduction of DNMT1 activity causes myeloid biased 
differentiation (Chavez, Jozefczuk et al. 2010). In contrast, lymphoid lineages 
depend on acquisition of DNA methylation (Ji, Ehrlich et al. 2010). These differences 
in the DNA methylome between the two lineages can explain the drive towards 
myeloid lineages when the DNA methylation machinery is deregulated. Combined 
reduction of DNMT3A and DNMT3B has however demonstrated an enhanced self-
renewal capacity and decreased differentiation potential (Challen, Sun et al. 2014). 
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Histone modifications also contribute to the regulation of HSC differentiation. 
Erythroid and myeloid differentiation from CMP has been linked to HDAC1 
expression (Wada, Kikuchi et al. 2009), and CMPs have a poised chromatin state 
with H3K4me3 and H3K27me3 enrichment, and upon further differentiation, 
H3K4me1 and H2A.Z levels increase (Cui, Zang et al. 2009, Abraham, Cui et al. 
2013). 
1.2.2 Transcriptional regulation of hematopoiesis 
In the differentiation process, networks of growth factors and TFs drive lineage 
commitment (Gottgens 2015). TFs shape the epigenome and hence provide a 
crucial regulation by either favoring a certain HSC fate or pushing forward to a 
lineage commitment, leading to mature blood cells. There are sets of TFs that are 
important for preserving the stem cell identity as well as production of the HSCs 
(Orkin and Zon 2008) (Figure 5). The regulatory TFs that are thought to regulate the 
myeloid lineage commitment are GATA1, PU.1 and RUNX1 (Ferreira, Ohneda et al. 
2005, Chou, Khandros et al. 2009). Commitment to the lymphoid lineage and 
lymphoid cell identity requires activation of E2A, Ebf1 and PAX5 in a linear manner 
(Nutt and Kee 2007, Zandi, Bryder et al. 2010).   
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Figure 5. Transcription factors important in hematopoiesis. 
TFs active in different stages of the hematopoietic differentiation process are illustrated in 
red. TFs that have not (yet) been demonstrated to be translocated or mutated in 
human/mouse are in light font. The remaining TFs, in bold font, have been associated with 
chromosomal translocations or somatic mutations in hematological malignancies. Figure 
reprinted with permission from publisher (Orkin and Zon 2008).  
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1.3 MYELOID MALIGNANCIES 
Myeloid malignancies refers to diseases originating from cells of myeloid origin, as 
opposed to cells of lymphoid origin, all developed from a common HSC. 
1.3.1 The myelodysplastic syndromes  
The myelodysplastic syndromes (MDS) consist of a heterogeneous group of clonal 
hematologic stem cell disorders, characterized by ineffective hematopoiesis that 
leads to low peripheral blood cell counts (Bejar, Stevenson et al. 2011, Montalban-
Bravo and Garcia-Manero 2018). In the majority of cases, the bone marrow is 
hypercellular, however the blood cells produced are dysplastic and the majority of 
these cells undergo apoptosis before reaching the peripheral circulation, leading to 
an inefficient hematopoiesis resulting in peripheral blood cytopenia where almost all 
patients have anemia, sometimes in combination with thrombocytopenia and or 
neutropenia.   
1.3.1.1 Diagnostic tools 
The international prognostic scoring system (IPSS) for risk stratification of MDS 
patients was introduced in 1997 (Greenberg, Cox et al. 1997), and revised in 2012 
giving rise to the currently used revised IPSS score (IPSS-R) (Greenberg, Tuechler 
et al. 2012). The IPSS-R takes into account bone marrow blasts, hemoglobin, 
platelet and neutrophil count, age and cytogenetic risk and divides the patients into 
five cytogenetic subgroups (Very good, Good, Intermediate, Poor and Very poor) 
(Table 1) (Greenberg, Tuechler et al. 2012, Greenberg 2013, Della Porta, Tuechler 
et al. 2015).  
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Table 1: Prognostic classification of MDS patients with IPSS-R (adapted from 
publisher with permission (Greenberg, Tuechler et al. 2012)).  
 
 
1.3.1.2 Mutational landscape in MDS 
In 2011, several groups described the presence of common somatic heterozygous 
mutations in MDS patients (Bejar, Stevenson et al. 2011, Malcovati, Papaemmanuil 
et al. 2011, Papaemmanuil, Cazzola et al. 2011, Thol, Bollin et al. 2014). These 
mutations are found in genes coding for proteins involved in DNA methylation, 
chromatin regulation, RNA splicing, transcription regulation, DNA repair, cohesion 
function or signal transduction (Papaemmanuil, Gerstung et al. 2013, Haferlach, 
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Nagata et al. 2014). However, as of yet, none of these mutations are included in the 
diagnostic criteria of MDS, apart from the splicing factor mutation SF3B1 is 
associated with ring sideroblast anemia and associated with good prognosis (Arber, 
Orazi et al. 2016).  
The clinical implication of these mutations is currently under intense investigation, 
and likely the mutations have bearing for risk of AML progression, and chance of 
response to different forms of therapy.   
The TET2 gene is frequently mutated in MDS (Figure 6), however the clinical 
implications of the TET2 mutation remains to be defined, as studies so far report 
conflicting results. There are studies where TET2 mutations did not have any impact 
on overall survival, but also reports of TET2 as a favorable prognostic marker 
(Kosmider, Gelsi-Boyer et al. 2009, Bejar, Stevenson et al. 2011, Bejar, Stevenson 
et al. 2012). 
Figure 6. Frequency of common mutations in different subgroups of MDS. Figure 
reprinted with permission (Haferlach, Nagata et al. 2014). 
 
When it comes to response to therapy, some studies have linked TET2 mutations to 
better response to the hypomethylating agents Azacitidine (AZA) and Decitabine 
(DAC) compared to patients without this mutation (Itzykson, Kosmider et al. 2011, 
Bejar, Lord et al. 2014). Mutations in the histone modulators ASXL1, EZH2 have 
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been associated with poor prognosis (Abdel-Wahab, Pardanani et al. 2011, Inoue, 
Kitaura et al. 2013), however a recent study demonstrated an increased survival and 
good treatment response to AZA (Tobiasson, McLornan et al. 2016). Mutations in 
TP53 and RUNX1 genes are clearly linked to poor overall survival (Tobiasson, 
McLornan et al. 2016). However, an individual patient commonly presents with 
several co-occurring mutations, which makes the prognostic evaluation more difficult 
(Hasegawa, Oshima et al. 2017).  
1.3.1.3 Epigenetic dysregulation in MDS 
Aberrant DNA methylation is generally associated with many cancers (Feinberg and 
Vogelstein 1983, Herman and Baylin 2003, Jones and Baylin 2007). As discussed in 
the previous section, mutations in the epigenetic machinery are common in 
myelodysplastic syndromes. With the recent technical advances it has been 
demonstrated that MDS patients have a global DNA hypermethylation (Figueroa, 
Skrabanek et al. 2009, Jiang, Dunbar et al. 2009). The aberrant methylation pattern 
compared to normal cells, has also been linked to progression to acute myeloid 
leukemia (AML) (Jiang, Dunbar et al. 2009) 
Despite the many studies on the MDS methylome, there are not many genes that 
have been shown experimentally to impact the MDS pathogenesis. One gene that is 
hypermethylated in MDS is p15, which is involved in cell cycle regulation. Promoter 
hypermethylation of p15 has been associated with poor prognosis and deletions of 
chromosome 5q and 7q (Uchida, Kinoshita et al. 1997, Quesnel, Guillerm et al. 
1998, Tien, Tang et al. 2001).  
Mutations in DNMT3A have been reported to be present in approximately 10 % of 
the MDS patients with no correlation to any cytogenetic subgroup, and have been 
associated with poor survival and faster progression to AML (Walter, Othus et al. 
2011, Ganguly and Kadam 2016). 
Apart from the mutations in the DNA methylation regulators (TET2, DNMT3A) there 
are also mutations in the histone modifying regulators (ASXL1, EZH2), which have 
been associated with poor prognosis (Abdel-Wahab, Pardanani et al. 2011, Inoue, 
Kitaura et al. 2013). 
 20 
1.3.1.4 Treatment options in MDS 
Based on the IPSS-R risk score, treatment choices are made. Therapy options for 
low risk patients are growth factors, supportive care and if del5q is present, 
lenalidomide (Montalban-Bravo and Garcia-Manero 2018). Patients in the higher-
risk groups are recommended treatment with the hypomethylating agents (HMA), in 
Sweden Azacitidine is administered in the clinic. If the patient has higher risk 
disease and is considered eligible for Allogeneic stem cell transplant, this 
procedure is performed, however the majority of patients are not eligible, due to 
age or comorbidities (Heuser, Yun et al. 2017). The efficacy of Azacitidine and 
Decitabine in higher risk MDS is well documented and HMA treatment leads to an 
increased overall survival, better quality of life and improvements of hemoglobin, 
platelets and neutrophils (Kantarjian, Issa et al. 2006, Fenaux, Mufti et al. 2009). 
However, only 50-60% of patients respond to HMA treatment, and all patients will 
eventually become treatment resistant. Several studies have investigated the 
impact of somatic mutations on response rate to HMA treatment, however studies 
show opposing results and this issue remains to be settled. Some studies have 
demonstrated that there are no differences in response rate between patients with 
and without mutations in DNMT3A, IDH1, IDH2, ASXL1 and EZH2 (DiNardo, 
Jabbour et al. 2016, Welch, Petti et al. 2016). Two other studies reported increased 
response to HMA with TET2 mutation in the absence of ASXL1 mutation (Itzykson, 
Kosmider et al. 2011, Bejar, Lord et al. 2014). ASXL1, that is usually associated 
with bad prognosis, has been linked to a better chance to respond to Azacitidine 
and increased survival in a recent study (Tobiasson, McLornan et al. 2016). 
1.3.2 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a heterogeneous clonal malignancy, with 
accumulation of immature blood cells in the bone marrow and the peripheral blood 
(O'Donnell, Abboud et al. 2012, Klepin 2015). The estimated median age of disease 
onset is around 70 years, making AML primarily a disease of the elderly, however 
the disease onset can come in any age (Klepin 2015). There are many subtypes of 
AML, based on morphological and cytogenetic aberrations, and also other genetic 
alterations like NPM1 and FLT3 mutations (Ref WHO 2016). Heterozygous somatic 
mutations are also found in AML making the molecular landscape of AML complex 
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and dynamic. Diagnostic and prognostic clinical methods for mutation detection are 
rapidly evolving (Dohner, Weisdorf et al. 2015) 
1.3.2.1 Diagnostic tools 
Bone marrow morphology, immunophenotyping, cytogenetics and molecular genetic 
testing are routinely used diagnostic tools, and AML is diagnosed if ≥20% blasts are 
seen in bone marrow smears (Dohner, Estey et al. 2017).  
Chromosomal abnormalities are found in approximately 55% of AML patients 
(Grimwade 2001, Mrozek, Heerema et al. 2004). In the WHO classification “AML 
with recurrent genetic abnormalities” eight translocations and their variants are 
represented (Arber, Orazi et al. 2016). Molecular genetic testing are used to screen 
mutations in disease category defining genes (NPM1, CEBPA and RUNX1), genes 
of prognostic and therapeutic value (FLT3) and mutations with unfavorable 
prognostic association (TP53 and ASXL1) (Gale, Green et al. 2008, Bowen, Groves 
et al. 2009, Pratcorona, Abbas et al. 2012, Schnittger, Eder et al. 2013, Haferlach, 
Nagata et al. 2014, Devillier, Mansat-De Mas et al. 2015, Tsai, Hou et al. 2016). 
1.3.2.2 Mutational landscape  
Mutations in the DNA methyltransferase 3A gene (DNMT3A) and isocitrate 
hydroxygenase genes (IDH1 and IDH2) were one of the first mutations that were 
discovered in AML (Cancer Genome Atlas Research, Ley et al. 2013, Dohner, 
Weisdorf et al. 2015). Several studies have investigated the clonal evolution in AML, 
concluding the presence of a phylogenic tree of mutations in both human and mouse 
models (Jan, Snyder et al. 2012, Corces-Zimmerman, Hong et al. 2014). 
Emphasizing that mutations in genes with epigenetic function (DNMT3A, TET2 and 
ASXL1) occur in preleukemic progenitor cells prior to leukemogenesis. However, 
these mutations have almost never been found as isolated clones indicating that 
they are not enough to drive the leukemogenesis (Papaemmanuil, Gerstung et al. 
2016).  
Tyrosine kinase-RAS receptor pathway mutations were observed to occur late and 
often more than once in the same patient (Paschka, Du et al. 2013, Corces-
Zimmerman, Hong et al. 2014, Groschel, Sanders et al. 2015). The cooperation of 
mutations in FLT3 and RUNX1 have been associated with induction of AML patients 
(Behrens, Maul et al. 2017)  
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Mutations in NMP1 gene occurred usually as a secondary hit after mutations in 
DNMT3A, IDH1 and NRAS (Papaemmanuil, Gerstung et al. 2016). The different 
molecular mutations in AML and their frequencies are presented in Figure 7.  
 
Figure 7: Frequency of common molecular mutations in adult AML. Figure reprinted 
with permission from publisher (Dohner, Estey et al. 2017).  
 
Together with the advances in the molecular landscape of AML the risk stratification 
has been updated recently, grouping patients into favorable, intermediate and 
adverse risk categories (Table 2) (Dohner, Estey et al. 2017). 
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Table 2. Risk stratification in AML (Dohner, Estey et al. 2017).  
 
 
1.3.2.3 Epigenetic dysregulation in AML 
The methylome in AML is generally hypermethylated in promoter CpG islands (CGI) 
and hypomethylated in the gene bodies however the methylation aberrations vary to 
a great extent between the different subtypes in AML (Alvarez, Suela et al. 2010, 
Bullinger, Ehrich et al. 2010, Deneberg, Guardiola et al. 2011). The epigenetic 
alterations in AML influence factors involved in regulation of DNA methylation 
(DNMT3A, IDH1, IDH2, TET), chromatin modulators and histone modifications (MLL 
fusions, MLL-PZD, EZH2, ASXL1) (Krivtsov and Armstrong 2007, Conway O'Brien, 
Prideaux et al. 2014). Another component involved in the epigenetic machinery 
found to be mutated in AML is the cohesion complex, which has the role to organize 
the chromatin in order to promote intra- and inter-chromosomal interactions (Welch, 
Ley et al. 2012, Leeke, Marsman et al. 2014, Thol, Bollin et al. 2014). Such 
mutations have been related with mutations in NPM1 and RUNX1 genes (Thota, 
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Viny et al. 2014). The clinical outcome of mutations in epigenetically active genes is 
complex and in need of further investigation. One example of this is that the majority 
of healthy people in the general population with these mutations (DNMT3A, ASXL1, 
TET2) do not develop AML (Genovese, Kahler et al. 2014, Jaiswal, Fontanillas et al. 
2014, Xie, Lu et al. 2014).  
1.3.2.4 Treatment options in AML 
 
The first choice of treatment in AML is induction chemotherapy, with a combination 
of cytarabine and anthracycline (most often daunorubicin) (Dombret and Gardin 
2016). Thereafter, consolidation chemotherapy is administered in order to 
aggressively target the leukemic cells (Mayer, Davis et al. 1994, Schlenk 2014). 
Not all patients can tolerate intensive chemotherapy, and patients may be selected 
for other options like Azacitidine (Dohner, Estey et al. 2017). 
 
Several studies have investigated the clinical outcome of treatment with Azacitidine 
in AML. Patients with newly diagnosed AML, being both fit and unfit for intensive 
chemotherapy (IC) (Dombret and Gardin 2016), and patients with 
relapsed/refractory AML, demonstrated a similar overall survival with Azacitidine 
compared to IC patients (Ivanoff, Gruson et al. 2013, Itzykson, Thepot et al. 2015).  
Chemotherapy has often many off-target effects with little overall cure rate in most 
patients with AML, emphasizing the need of more targeted therapy (Lazarevic, 
Bredberg et al. 2018).  
 
1.3.3 Systemic mastocytosis  
Systemic mastocytosis (SM) is a clonal bone marrow malignancy with an activating 
point mutation at codon 816 (D816V) in the catalytic domain of the stem cell factor 
receptor KIT, which leads to increased survival and proliferation of mast cells 
(Metcalfe and Mekori 2017). Patients with SM suffer from accumulation of clonal 
mast cells (MCs) in various organs (Valent, Akin et al. 2017).  
More than 95% of the patients carry the KIT D816V mutation, and the paradox of SM 
is that the same KIT D816V mutation may give an indolent or aggressive clinical 
phenotype.  There is a correlation between disease symptoms and the allelic burden 
of KIT D816V mutation (Kristensen, Broesby-Olsen et al. 2013, Meni, Bruneau et al. 
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2015), however likely there are additional, unknown factors that determine whether 
the patient will have an indolent or aggressive SM disease.  
The clinical features of SM consist of a broad spectrum of symptoms from various 
organs (Metcalfe 2008, Teodosio, Garcia-Montero et al. 2010, Jawhar, Schwaab et 
al. 2016). Symptoms vary from flushing, hypotension, nausea, vomiting, abdominal 
cramping, headaches, psychiatric symptoms, to anaphylaxis (Metcalfe and Mekori 
2017). 
1.3.3.1 Diagnostic tools 
The major criteria for SM include a multifocal accumulation and clustering of MCs in 
the bone marrow or other extra cutaneous organ. The clonal nature, abnormal MC 
morphology, expression of the lymphoid related antigens CD2 and CD25, presence 
of KIT D816V mutation, and a basal tryptase level over 20 ng/mL are included in 
the minor criteria of SM (Valent, Akin et al. 2017). When one major criterion and at 
least one minor criterion, or at least three minor criterions are fulfilled the patient is 
diagnosed with SM (Valent, Akin et al. 2017). 
The different subgroups in systemic mastocytosis consists of indolent systemic 
mastocytosis (ISM), smoldering systemic mastocytosis (SSM), systemic 
mastocytosis with associated hematological neoplasm (SM-AHN), aggressive 
systemic mastocytosis (ASM), and MC leukemia (MCL) (Valent, Akin et al. 2017). 
Patients with indolent SM may have severe symptoms but have a normal life 
expectancy (Pardanani 2016).  SM-AHN is frequently found, that is patients with 
indolent or aggressive SM are found to have another hematological non mast cell 
disease, most frequently MDS of various subtypes. In SM-AHN, survival depends on 
the AHN disease. Patients with ASM and MCL have the worst prognosis, with 
usually a survival time of 2 to 4 years for ASM and only months up to one year for 
MCL.  
1.3.3.2 Treatment options in SM 
In indolent SM, symptom control is vital, using histamine blockers (H1 and H2) for 
blocking the effects of mast cell histamine release, and sometimes leukotriene 
antagonists. 
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For patients with advanced SM the treatment options include several cytoreductive 
therapies, such as 2-Chlorodeoxyadenosine (2-CDA), interferon-alpha (IFN-α) in 
combination with steroids, or sometimes classical chemotherapy agents (such as 
cytarabine or fludarabine) (Pardanani 2016). However, no chemotherapeutic agent 
has proven an improved survival in ASM. In the case of SM-AHN, it is recommended 
to treat the AHN, e.g. hydroxyurea of the AHN is a myeloproliferative neoplasm, and 
Azacitidine or growth factors if the AHN is MDS. 
In recent years, the pan tyrosine kinase inhibitor midostaurin has been approved for 
ASM and MCL (DeAngelo, George et al. 2018), however despite the promising 
results, midostaurin has not yet demonstrated an improved survival rate, thus there 
is still a need for targeted therapy in SM.  
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1.4 EPIGENETIC DRUGS   
1.4.1 Azacitidine 
The DNA consists of two polynucleotide strands that form a double helix. The four 
nucleobases that shape the DNA are adenine (A), guanine (G), cytosine (C) and 
thymine (T). Azacitidine (AZA) is a structural analog to cytidine. When AZA is taken 
up in the cell, 80-90% is converted into ribonucleoside triphosphate by uridine-
cytidine kinase (UCK) leading to incorporation into RNA and further inhibition of 
protein synthesis A fraction (10-20%) of the diphosphate forms of AZA is further 
reduced into deoxy- (DAC)-diphosphates, by ribonucleotide reductase (RR), that can 
be incorporated into DNA (Aimiuwu, Wang et al. 2012). 
Early studies have shown that AZA was preferentially targets malignant cells but not 
dividing healthy cells (Glover and Leyland-Jones 1987). Additional studies concluded 
targeting of DNA hypermethylation mainly via DNMT1 depletion (Kaminskas, Farrell 
et al. 2005, Estey 2013).   
1.4.1.1 Molecular mechanisms of action of AZA and DAC 
Although AZA and DAC have been used in the clinic for the past three decades the 
exact mechanism of action is not clear, and several different mechanisms of action 
have been proposed. Below, three different mechanism of action of AZA and DAC, 
which can perhaps explain the differences in the clinical outcomes, are being 
described. 
(A) DNMT1 depletion mechanisms dependent on DNA replication  
The proposed mechanism of action of histone hypomethylating agents (HMA) is 
established on the ability of the HMA to mimic normal cytidine and incorporate into 
DNA, leading to inhibition of methylation by DNMTs. The inhibition is due to the 
replacement of cytosine carbon in position 5 with a nitrogen group in AZA and DAC 
analogous, leading to an irreversible covalent bond with DNMT1 that is depleted 
upon replication. Depletion of DNMT1, which is important for maintaining DNA 
methylation during replication, leads to reduced overall DNA methylation marks in 
the daughter cells and an increased gene expression. The idea is that the tumor 
suppressor genes will be re-activated and hence block the malignant proliferation 
(Figure 8A). 
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 (B) DNMT1 depletion mechanisms independent on DNA replication  
Several studies have emphasized the need of a DNA replication independent 
depletion of DNMT1. The rationale behind this is due to observations of decreased 
DNMT1 activity faster than incorporation of HMA to DNA, depletion of DNMT1 even 
in the absence of DNA replication and cell division, and the incorporation of AZA 
into DNA (Creusot, Acs et al. 1982, Aimiuwu, Wang et al. 2012).  
The proposed DNA replication independent mechanism occurs through the protein 
kinase C delta (PKCd) which hyperphosporylates DNMT1 directing it to rapid 
proteosomal degradation via the ubiquitination system (Pleyer and Greil 2015) 
(Figure 8B).  
(C) RNA dependent inhibition mechanisms of RR  
The majority of AZA is incorporated into RNA as described earlier, giving rise to 
apoptosis through the disruption of mRNA and protein metabolism (Aimiuwu, Wang 
et al. 2012). 
The rate-limiting enzyme ribonucleotide reductase (RR) generates the basic 
building blocks (deoxyribonucleotides) of DNA synthesis through its two subunits, 
RRM1 and RRM2. Studies have demonstrated the decrease of RRM2 mRNA 
stability and inhibition of RRM2 gene expression upon AZA incorporation into RNA 
(Aimiuwu, Wang et al. 2012). Inhibition of RR leads to decreased intracellular levels 
of the four deoxyribonucleotides (Figure 8C).  
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Figure 8: Schematic illustration of different mechanisms of action of AZA and DAC. 
The three proposed mechanisms of action of AZA/DAC are depicted. (A) DNA replication 
independent mechanism. (B) DNA independent mechanism. (C) RR replication dependent 
mechanism. Figure reprinted with permission from publisher (Pleyer and Greil 2015). 
 
1.4.2 Histone deacetylase inhibitors (HDACi) 
Histone deacetylation prevents gene expression through removal of acetyl groups on 
acetylated lysine histones, but histone deacetylases also target non-histone proteins 
such as α-tubulin, nuclear transporter proteins, chaperones (HSP90 and HSP70) 
and TFs (p53, c-myc, NFkβ) (Glozak, Sengupta et al. 2005, Minucci and Pelicci 
2006). Mutations in many HDACs have been observed in a variety of disorders, 
making HDACi an attractive treatment option (Mai, Massa et al. 2005). HDACi 
targets transformed cells via cell cycle arrest, inhibition of angiogenesis and 
induced apoptosis (Marks, Rifkind et al. 2001, Paris, Porcelloni et al. 2008).  
HDACi are classified into different groups depending on their chemical structures, 
which consists of hydroxamic acids, cyclic peptides, electrophilic ketones, short-
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chain fatty acids, benzamides, boronic acid-based compounds, benzofuranone and 
sulfonamide-containing molecules and α/β peptide structures (Marks and Breslow 
2007, Wang, Hevi et al. 2009). There are three functional chemical components of 
hydroxamic acids; a zinc-binding moiety (ZBM) in the catalytic domain, opposite 
capping group and a linker group consisting of a straight-chain alkyl, vinyl or aryl. 
The main task of these functional groups is to interact with the catalytic pocket of 
HDACs.  They are further subdivided into which class of HDACs they inhibit. 
SAHA (also referred to Vorinostat) was one of the first HDACi that was approved by 
the U.S Food and drug Administration (FDA) in treatment of cutaneous T-cell 
lymphoma (Mann, Johnson et al. 2007). SAHA is a non-selective/pan HDACi, which 
acts as a chelator for the zinc ions in the catalytic domain of histone deacetylases, 
resulting in inhibition of the HDACs to remove acetyl groups from lysine histones. 
This leads to increased expression of genes due to the accumulation of acetylated 
histones, acetylated proteins and also increasing the expression of TFs important for 
cell differentiation. SAHA has been demonstrated to induce gene expression of 
downregulated genes in myeloid malignancies, and suppressed genes that were 
overexpressed (Silva, Cardoso et al. 2013). Currently there are various HDACi that 
have either been approved or are in clinical trials (Table 3) (Ungerstedt 2018). 
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Table 3. HDACis in clinical trials (Ungerstedt 2018). 
 
 
1.4.3 Selenium compounds 
Selenium (Se) is present in a variety of biologically active compounds such as in the 
antioxidant regulatory system, glutathione peroxidases (GPx), thioredoxin 
reductases (TrxR) and iodothyronine deiodinases (DIO), the thyroid hormone 
metabolism and in regulating the endoplasmatic reticulum homeostasis (Papp, Lu et 
al. 2007). 
The epigenetic effects of Se have been reported in several studies. Se has been 
reported to affect global and gene-specific DNA methylation and the expression of 
DNMTs (Arai and Kanai 2010). Studies with in vitro human and animal models have 
demonstrated an inverse correlation of Se with DNA methylation and DNMT activity 
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(Armstrong, Bermingham et al. 2011, de Miranda, Andrade Fde et al. 2014, Yang, 
Zhu et al. 2014).  
Selenium compounds have also been linked with inhibition of HDAC activity in 
several studies (Lee, Nian et al. 2009, Desai, Salli et al. 2010, Kassam, Goenaga-
Infante et al. 2011, Gowda, Madhunapantula et al. 2012). Two derivatives of HDACi 
containing Se have demonstrated a higher inhibitory activity against HDACs 
compared to commercially available HDACi, the clinical implications remains yet to 
be investigated (Desai, Salli et al. 2010). 
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2 AIM OF THE THESIS 
The overall aim of this thesis is to explore the epigenetic aberrations in the myeloid 
malignancies myelodysplastic syndromes (MDS), systemic mastocytosis (SM), and 
acute myeloid leukemia (AML), in order to better understand the pathobiology of 
these diseases, and understand the mechanism of action of epigenetically active 
drugs in myeloid malignancies. 
The specific aims for papers I-IV were: 
 
Paper I: To evaluate the genome-wide epigenetic status of primary MDS patient 
stem/early progenitor cells, and to study the treatment effects of Azacitidine. 
 
Paper II: To assess whether HDACi treatment have may have therapeutic potential 
in D816V KIT mutated SM cells, and assess whether this effect is selective for 
mutated mast cells compared to healthy. 
 
Paper III: To investigate if the antitumor effects of selenium in AML can be explained 
by selenium affecting epigenetic regulatory mechanisms. 
 
Paper IV: To delineate the epigenetic mechanisms of action of HDACi in SM.  
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3 METHODOLOGICAL APPROACHES  
3.1 GENOME-WIDE DNA METHYLATION ANALYSIS  
During the last decade, DNA methylation analysis has scaled up from locus-specific 
methods to a genome-wide level due to the recent advances of next-generation 
sequencing (NGS) platforms, which provide the advantages of single-base resolution 
(Yong et al., 2016). The various experimental methods to study DNA methylation 
can be divided into three main methodologies: enzyme digestion, affinity enrichment 
and bisulfite conversion.  
Restriction enzyme‑based methods use DNA methylation sensitive enzymes, which 
cleaves only unmethylated sites, leaving the methylated DNA intact. In affinity 
enrichment-based methods methyl-CpG-binding domain (MBD) proteins or 
antibodies specific for 5mC are used in order to pull down methylated DNA regions. 
In bisulfite conversion-based methods the DNA is treated with sodium bisulfite, 
which will deaminate unmethylated C to uracil, and eventually to thymine through a 
chain of PCR amplification steps, and methylated C will be unaffected.  
Since the main principles to study DNA methylation mentioned above can’t 
differentiate between 5mC and 5hmC, there has been a growing field of new 
experimental modifications to distinguish between these two methylation states. For 
example the Oxidative bisulfite sequencing (OxBS‑seq), in which the DNA is treated 
with an oxidizing agent prior to bisulfite treatment.  Leading to the conversion of 
5hmC to 5fmC, which is further converted to uracil during bisulfite treatment and 
being read as thymine in the sequencing stage. The 5mC will not be oxidized and 
will be detected as C in the sequencing step (Kirschner, Krueger et al. 2018). 
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Figure 9: Schematic illustration of different genome-wide DNA methylation assays. 
The four main steps in genome-wide DNA methylation assays are (1) fragmentation of DNA, 
(2) enrichment, (3) bisulfite conversion and (4) analysis. Figure reprinted with permission 
from publisher (Lee, Ryu et al. 2018).  
 
Each of the above-mentioned approaches could then either be analyzed through gel-
based methods, array-based methods or NGS based methods (Figure 9) (Lee, Ryu 
et al. 2018). As with all methods there are strengths and limitations to take into 
consideration when choosing a method to analyze genome-wide DNA methylation. 
One important aspect to take into consideration is the CpG coverage throughout the 
genome and resolution. Both restriction enzyme- and affinity-based approaches 
have a poor coverage in regions with low CpG density, the restriction enzyme sites 
and the antibody affinity also limits the coverage. The bisulfite conversion-based 
methods have the best coverage, being more sensitive in regions with low CpG 
density. Whole-genome bisulfite sequencing (WGBS) gives rise to the best coverage 
and a single-base resolution, however this method requires large amount of DNA 
material due to extensive sequencing and is very expensive (Soozangar, Sadeghi et 
al. 2018).  Reduced-representation bisulfite sequencing (RRBS) is a good alternative 
to WGBS, providing an accurate and cost effective method for genome-wide DNA 
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methylation mapping. In this thesis the Illumina human methylation 450K-array 
method was used to evaluate the global DNA methylation maps. 
3.1.1 Illumina 450K array 
The Illumina human methylation 450K arrays is an affordable alternative to WGBS; it 
covers approximately 480,000 CpG sites and 99% of the RefSeq genes (hg19) (Sun, 
Cunningham et al. 2015). With this method it is possible to study genome-wide 5mC 
DNA methylation patterns. However, it is not possible to distinguish between 5hmC 
and 5mC, unless the OxBS treatment is implemented prior to sequencing.  
Illumina replaced the 450K beadchip to the Epic BeadChip (>850,000 CpG sites), 
covering approximately 90% of the CpG sites represented on the 450K beadchip 
(Logue, Smith et al. 2017). A recent correlation study of same sample sets run on 
both Epic BeadChip and 450K array, showed 94% of overlapping differentially 
methylated probes (Pidsley, Zotenko et al. 2016). 
The Illumina methylation array utilizes probes with specificity towards individual CpG 
sites across the genome, and the methylation level is quantitatively measured by 
genotyping the bisulfite treated genomic DNA. The 450K arrays use the chemistry of 
two assays, Infinium I and II. The difference between the two technologies lies in the 
probe detection of methylated and unmethylated DNA; Infinium I uses two different 
probes to detect methylated and unmethylated DNA, giving rise to one color (blue) in 
the readout, whereas Infinium II only uses one bead type which can detect 
methylated signal in green and unmethylated signal in red (Bibikova, Barnes et al. 
2011, Sandoval, Heyn et al. 2011). The signal is then reported as β-value, which 
resembles a percentage of methylated probe intensity versus the sum of overall 
intensity (methylated and unmethylated probe intensities) (Dedeurwaerder, Defrance 
et al. 2011). β-value ranges from 0 (unmethylated) to 1 (fully methylated). M-value, 
another method to measure methylation level, is a log2 ratio of the intensities of 
methylated versus unmethylated probes (Du, Zhang et al. 2010). There are pros and 
cons in using any of the methods; the β-value is easier to interpret from a biological 
point of view, but the interpretation is an approximation and is strongly influenced by 
the normalization process. The M-value on the other hand is a better statistically 
valid method, however is does not have a straightforward biological interpretation. It 
is recommended to use M-value in differential methylation analysis, and also to 
report the β-value statistics in the final report (Du, Zhang et al. 2010). M-value was 
used in paper I to analyze the differential methylation levels after treatment.  
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3.2 CHROMATIN ACCESSIBILITY AND MODIFICATION ANALYSIS 
There are several methods available to study the accessibility of the chromatin; one 
such method is the Assay for transposase-accessible chromatin using sequencing 
(ATAC-seq) (Buenrostro, Giresi et al. 2013). With this approach regions that are 
accessible for transcription, will be cut by the Tn5 transposase, and adapters for 
high-throughput sequencing will be ligated to the fragments. Subsequent sequencing 
will give rise to genome-wide mapping of the chromatin accessibility (Buenrostro, Wu 
et al. 2015). 
Another way to study the chromatin dynamics is to study the posttranslational 
modifications (PTMs) on the histone proteins, which will either give an active or 
repressed chromatin state. Chromatin immunoprecipitation followed by next 
generation sequencing (ChIP-seq) is one such technique that enables to study the 
histone PTMs (Kidder, Hu et al. 2011). 
3.2.1 Chromatin immunoprecipitation sequencing  
The first step in a ChIP-seq experiment is formaldehyde fixation to crosslink DNA-
binding protein to DNA; thereafter the chromatin is fragmented by sonication, into 
fragments of 200-600 bp, thereafter the region of interest is pulled down with an 
antibody that targets the modification of interest. After the immunoprecipitation step, 
DNA is released and purified, and the DNA-protein fragments of interest are 
prepared for sequencing. The preparation step is also referred to as library 
construction, which involves ligation of sequencing adapters and barcodes, in order 
to be able to pool several samples, and PCR amplification steps before eventually 
being analyzed by sequencing. Since there will be a lot of noise in the ChIP-seq 
data, a region that has not been immunoprecipitated, input, is also sequenced as a 
background control. 
A first step in the analysis of the ChIP-seq data is an evaluation of the quality of the 
sequencing data, and filtering out bad quality reads. The filtered reads are then 
mapped to a reference genome by the use of different algorithms (Bailey, Krajewski 
et al. 2013). 
One of the main tasks in the bioinformatics analysis of ChIP-seq data is to predict 
regions that are bound by a specific histone modification or transcription factor, this 
is done by calling peaks. There are several algorithms that can perform peak calling 
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(Bailey, Krajewski et al. 2013); the overall aim is to define regions with tags (reads) 
higher than the background (input).  
There are many factors to consider when performing ChIP-seq experiments, the 
choice of antibody is one of the most important factor when it comes to generating 
high quality data. It is therefore important to choose an antibody that is specific and 
sensitive both for the assay and for the protein of interest (Kidder, Hu et al. 2011). 
In paper I the histone modifications H3K9me3 and H3K18ac were studied by ChIP-
seq. In paper II, H3K9me3, H3K27ac and H3K18ac were analyzed by ChIP-qPCR. 
In paper III, the epigenetic effects caused on the histone marks H3K9me3, H3K9ac 
and H3K4me3 were investigated using ChIP-seq.  In paper IV H3K9me3, H3K27ac 
and H3K4me3 were studied by ChIP-seq. The quality metrics of the raw data was 
checked with the FASTQC tool, and Bowtie2 was used to align the reads to the 
human reference genome. Peak calling was performed with HOMER algorithm.  
3.2.2 Assay for transposase-accessible chromatin using sequencing (ATAC-
seq) 
Profiling nucleosome occupancy and chromatin accessibility is of great importance 
when performing genome-wide epigenetic studies. As mentioned earlier ATAC-seq 
is one approach that can be used in chromatin accessibility studies (Bailey, 
Krajewski et al. 2013). ATAC-seq experiments consists of Tn5 transposase cleavage 
on unfixed nuclei from 50 000 sorted cells. After the transposition reaction the DNA 
is purified, and libraries are prepared through PCR amplification with sequence 
specific adapters. Amplified libraries are then purified, quantitatively and qualitatively 
controlled before being analyzed by high-throughput sequencing.  
ATAC-seq data processing is of great importance, and there are several different 
algorithmic tools available (Miskimen, Chan et al. 2017).  The analysis workflow 
involves quality assessment of raw data, removal of bad quality reads and adapter 
sequences, alignment to reference genome and peak detection. 
In paper III ATAC-seq was used as a method of choice to investigate the chromatin 
accessibility in mutated mast cells upon HDACi treatment.  
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3.3 TRANSCRIPTOME PROFILING 
The total amount of transcripts and their quantity in a cell at a specific developmental 
stage or condition is defined as the transcriptome (Wang, Fang et al. 2010). In order 
to understand the phenotypically or functionally specific characteristics of a cell type 
it is of great importance to study the transcriptome of that specific cell. With the 
increasing access to affordable high-throughput sequencing platforms, it is possible 
to map and quantify transcriptomes on a genome-wide level (McGettigan 2013). The 
method applied to both map and quantify transcriptomes is referred to as RNA 
sequencing (RNA-seq). In this thesis, messenger RNA (mRNA) sequencing was 
applied in paper I, paper III and paper IV.  
3.3.1 Messenger RNA Sequencing  
The first step in the RNA-seq experimental workflow is to extract the RNA of interest, 
in this case the mRNA. Since ribosomal RNA (rRNA) is highly abundant in a cell, 
constituting of approximately 90% of the total RNA content, it is therefore crucial to 
use good extraction protocols yielding pure mRNA. The RNA quality is assessed 
with a technique called bioanalyzer, which measures the RNA integrity number 
(RIN). The RIN value is ranging from fully degraded RNA to intact RNA (1-10), a RIN 
value of at least 8 is required for a good library construction and sequencing. The 
next step is to synthesize and purify cDNA libraries, thereafter ligation of sequencing 
adapters and amplification of the cDNA libraries are performed before analysis by 
NGS sequencing.  
The sequencing workflow generally starts with hybridizing the libraries on a flow-cell; 
thereafter clusters are generated in a stepwise synthesis to generate identical DNA 
strands that are covalently bound to the flow-cell surface. The amount of starting 
material that is loaded on the flow-cell is the limiting factor for the clusters density.  
After quality metric assessment of the sequencing data, the reads are mapped to the 
reference genome, and genes can be annotated. Gene expression is then 
quantitatively measured by counting tags in each annotated gene, similar to peak 
calling algorithms. The signal is then reported as normalized expression such as 
reads per kilobase of exon model per million mapped reads (RPKM), fragments per 
kilobase of exon model per million mapped reads (FPKM) or trimmed mean of M-
values (TMM) or median count ratio (Mutz, Heilkenbrinker et al. 2013). Differential 
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expression analysis is then performed with tools such as EdgeR, Noiseq and DEseq 
(Conesa, Madrigal et al. 2016). 
In paper I a modified version of mRNA-seq was used, referred to as single-cell 
tagged reverse transcription (STRT) RNA-seq. This method measures transcription 
initiation at the 5′end of polyA+ transcripts starting from 10 ng of mRNA as template 
(Islam, Kjallquist et al. 2012, Krjutskov, Katayama et al. 2016). In paper III and IV 
traditional quantitative mRNA sequencing was used. 
3.4 INTEGRATIVE BIOINFORMATIC ANALYSIS 
 
The advances in technical approaches in data generation from several layers of 
biological systems have lead to a growing field of bioinformatic tools, that can 
assist in the pursue of understanding the complex biological networks. An 
integrative bioinformatic approach can be more informative of the genotype-
phenotype associations than analyzing a single type of data. However, it is 
important to keep in mind the different layers of biological regulation, in order for 
the integrative approach to be successful as a biological model (Holzinger and 
Ritchie 2012). It is also crucial to consider the limitations with each single data type 
before combining them in a meta-dimensional analysis.  
 
The integration process can be divided into multi-stage analysis, where only two 
types of data is integrated stepwise, or meta-dimensional analysis, simultaneous 
integration of all types of data. The multi-stage analysis is based on a biological 
hypothesis that a phenotype is driven by a hierarchical variation, meaning changes 
in genome leads to changes in the transcriptome which gives rise to changes in the 
proteome. The meta-dimensional analysis on the other hand is driven by the 
hypothesis that variation in all of the different omics (genome, epigenome, 
transcriptome and proteome) gives rise to the phenotype (Ritchie, Holzinger et al. 
2015).   
 
The limitations with using statistical prediction models to understand complex 
biological systems is first and foremost the estimation of the power; some methods 
calculate power from theoretical distributions while others require simulation 
observations (Ritchie, Holzinger et al. 2015). Finding meaning and true significance 
in the different data sets also creates another level of difficulty in the translational 
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interpretation of the integrative analysis (Davis-Turak, Courtney et al. 2017)).  
In the studies conducted in this thesis integration of DNA methylation data, RNA-
seq data and ChIP-seq data were performed in paper I in a multi-stage approach, 
to investigate the correlation of changes in DNA methylation landscape to gene 
expression and histone PTMs. In paper III, ChIP-seq and RNA-seq was integrated. 
In paper IV, chromatin accessibility and modification was correlated to gene 
expression through the integration of ATAC-seq, ChIP-seq and RNA-seq. 
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4 RESULTS AND DISCUSSION 
The four studies included in this thesis investigate the effect on the epigenome after 
treatment with epigenetically active drugs, in three different myeloid malignancies. In 
paper I, genome-wide DNA methylation was evaluated and correlated to gene 
expression and histone PTMs (H3K9me3 and H3K18ac), after treatment of MDS 
bone marrow progenitors with the DNA hypomethylating agent Azacitidine. In paper 
II, the effect of HDACi on D816V KIT mutated mast cell line and primary mast cells 
was investigated. Paper IV is a follow-up study of paper II, where the mechanism of 
action of the HDACi SAHA in D816V KIT mutated mast cells was further 
characterized.  In paper III, the epigenetic effects of selenium compounds on AML 
patient cells and a leukemic cell line, was investigated.  
4.1 PAPER I: COMPREHENSIVE MAPPING OF THE EFFECTS OF 
AZACITIDINE ON DNA METHYLATION, REPRESSIVE/PERMISSIVE 
HISTONE MARKS AND GENE EXPRESSION IN PRIMARY CELLS FROM 
PATIENTS WITH MDS AND MDS-RELATED DISEASE 
In this study, bone marrow samples were collected from a previously untreated 
patient cohort consisting of 6 higher-risk MDS, 4 AML with multilinear dysplasia and 
20–29% blasts (MDS/AML), and one patient with chronic myelomonocytic leukemia, 
CMML-2. All of the patients had a clinical indication to start Azacitidine (AZA) 
treatment. Mononuclear cells were isolated from bone marrow samples, and CD34+ 
progenitor cells were sorted using magnetic beads. CD34+ cells were incubated with 
and without AZA for 24h and 48h. Genome-wide methylation was profiled using 
Illumina 450K array, transcriptome analysis with STRT RNA-seq, and the histone 
modification mapping with ChIP-seq, using H3K18ac and H3K9me3 antibodies. 
We identified 65 769 differentially methylated probes (DMPs) after 24h treatment, 
when comparing samples cultured with and without AZA. The majority (n=65 664) 
was less methylated in the AZA treated samples. The distribution of DMPs across 
the genome was lower in the CpG islands and higher in the open sea probes, when 
compared to the Illumina 450k reference. Moreover, we observed lower DMPs in 
regions close to the TSS, and higher probes in regions located in gene bodies or 
non-gene related probes and regions defined as heterochromatin. However, the 
overall mean reduction in β-value was 0.018, which indicates a modest 
demethylation.  
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A significant increase in global gene expression was observed for all patients after 
24h AZA treatment. The upregulated genes were involved in translation, RNA 
processing and ribosomal function gene ontology pathways. When we correlated the 
global changes in DNA demethylation with the increased gene expression, we 
observed a weak correlation. This might be linked with the observation of 
demethylation mainly taking place in gene bodies and non-gene related probes and 
regions, emphasizing alternative triggers for the increased gene expression.  
In order to understand the changes in gene expression, we assessed if AZA 
treatment affected active (H3K18ac) or repressive (H3K9me3) histone marks. When 
we correlated DNA methylation changes with the changes in the repressive histone 
mark we observed a strong correlation. This supports the hypothesis that AZA may 
have a great effect in heterochromatin regions defined by H3K9me3. However, the 
correlation with the increased gene expression and histone marks showed weak 
correlation for H3K9me3, and no correlation at all for H3K18ac.  
Since the epigenetic changes could only partly explain the increase in gene 
expression we performed TF binding site analysis, by looking for enriched motifs in 
the significantly upregulated genes. We found motifs for eight transcription factors 
(ELK1, STAT 1, STAT3, RUNX1, GABPA, ERG, NRF1 and PU.1) that were 
significantly enriched, and also upregulated in expression. Hence, the increased 
gene expression may partly be explained by increase of the above mentioned TFs, 
many of which have important regulatory functions in hematopoietic differentiation. 
Hypothetically, the AZA effect may somewhat be through interfering with the 
differentiation process. The increased expression of the observed TFs could 
however not be explained by our epigenetic data, and the upstream regulation needs 
to be investigated.  
Correlation of gene expression data with regions defined as repetitive elements, 
illustrated significant increase of 16 transcript far 5’-ends (TFEs) overlapping with 
repetitive elements in AZA treated samples, and significant decrease in only three. 
Among the upregulated TFEs, 15 were members of the endogenous retroviruses 
(ERVs) family. Since there were no probes in the Illumina 450K array we could not 
assess the DNA methylation changes in those regions. Assessment of the changes 
of H3K9me3 peaks in the AZA samples compared to the control samples over the 
ERV regions, demonstrated no general reduction. 
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An activation of the 15 ERV containing transcripts was observed in the AZA 
samples, which is in line with previous studies on cell lines (Chiappinelli, Strissel et 
al. 2015, Roulois, Yau et al. 2016). However, with this study we demonstrate for the 
first time that AZA treatment results in ERV activation also in primary CD34+ MDS 
cells. Due to the short incubation time we were not able to investigate the response 
of the immune genes.  
Previous studies have demonstrated that DNA methylation during mammalian 
gametogenesis and early embryonic development give rise to activation of ERVs, 
which correlates with pluripotency (Macfarlan, Gifford et al. 2012). Therefore, it is 
possible that the observed increase in ERV expression in MDS cells could 
participate in cell differentiation upon AZA treatment. 
4.2 PAPER II: HISTONE DEACETYLASE INHIBITOR SAHA MEDIATES MAST 
CELL DEATH AND EPIGENETIC SILENCING OF CONSTITUTIVELY 
ACTIVE D816V KIT IN SYSTEMIC MASTOCYTOSIS  
In this study, we assessed the sensitivity of primary mast cells and mast cell lines, 
D816V mutated HMC1.2 and ROSA cells and KIT WT ROSA cells, to treatment with 
histone deacetylase inhibitors (HDACi), SAHA, Panobinostat, Romidepsin and 
Valproic acid. We observed a dose and time-dependent growth arrest and cell death 
of the KIT mutated HMC1.2 cells, with the greatest effect upon SAHA treatment. A 
global acetylated histone level was observed already after 2 hours of incubation with 
SAHA, and a decrease of active phosphorylated KIT at 6 hours. We observed 
decrease levels of cell surface KIT, KIT mRNA and total protein levels after 24 hours 
of treatment, which was followed by mast cell apoptosis.  
When assessing the sensitivity of SAHA on the primary mast cells, we observed a 
decrease in cell surface KIT and major cell death in the SM patient MCs compared 
to the age-matched healthy controls. The sensitivity was higher in the primary cells 
from patients with more aggressive SM disease compared to cells from ISM. 
Moreover, MCs from a patient with highly aggressive MCL were completely dead 
after 48h of SAHA treatment. Our findings demonstrate that the malignant mast cells 
with KIT mutation are more susceptible of the SAHA mediated killing compared to 
healthy mast cells. 
 In order to investigate the mechanism of action of SAHA in this context we 
assessed the changes of histone PTMs (H3K9me3, H3K27ac and H3K18ac) in the 
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KIT transcription start site, and a gene upstream (PDGFRα) and downstream (KDR) 
of KIT by ChIP-qPCR. The first observation was a general increase of the acetylated 
histone marks, as anticipated upon SAHA treatment.  However, a significant global 
increase of the histone H3 density in the KIT gene and the adjacent genes was 
observed after SAHA treatment. Taking this into consideration we calculated the 
enrichment for the histone marks relative to the total H3 density in each gene. The 
active chromatin marks (H3K27ac and H3K18ac) showed a significant decrease in 
the promoter region of KIT upon SAHA treatment, compared to the gene upstream 
and downstream which had unchanged levels. These findings are indicating that 
there might be an epigenetic response that closes the chromatin in the KIT gene, 
and leads to the SAHA mediated downregulation of KIT mRNA and protein levels.  
Altogether the conclusion from the findings in this study is that mast cells from 
aggressive SM show high sensitivity to SAHA, which may be clinically applicable as 
treatment for SM. 
The exact mechanism of action of SAHA as well as the selectivity towards mutated 
mast cells is investigated in paper IV. 
4.3 PAPER III: SELENITE AND METHYLSELENIC ACID EPIGENETICALLY 
AFFECTS DISTINCT GENE SETS IN MYELOID LEUKEMIA: A GENOME 
WIDE EPIGENETIC ANALYSIS 
The proposed epigenetic effects as well as cytotoxic effects of selenite and 
methylseleninic acid (MSA) were assessed in a leukemic cell line (K562) as well as 
primary AML patient cells. The activities of both active (H3K4me3 and H3K9ac) and 
repressive (H3K9me3) histones were assessed with ChIP-seq, and the gene 
expression effects were evaluated with RNA-seq. Both selenium compounds 
affected the histone marks, however the effect caused by MSA was more 
pronounced. Gene ontology analysis revealed that selenite and MSA affected 
different gene sets. The pathways affected by selenite, involved response to hypoxia 
and oxygen, while MSA on the other hand affected cell adhesion and glucocorticoid 
receptors. This indicates that selenite and MSA have different mechanism of actions. 
The findings were functionally confirmed by plating K562 cells and AML primary cells 
on fibronectin-coated plates; which demonstrated a decreased expression of integrin 
β and a loss of cellular adhesion upon MSA treatment, in AML cell line K562 as well 
as in primary patient AML cells. We postulate that this effect of MSA on adhesion 
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capacity may be utilized therapeutically, to release AML cells from protected stem 
cell niche into the circulation, where cells are more susceptible to chemotherapeutic 
drugs.  
4.4 PAPER IV: MECHANISTIC CHARACTERISATION OF SAHA MEDIATED 
D816V KIT DOWNREGULATION IN SYSTEMIC MASTOCYTOSIS 
The purpose of this study is to investigate the exact mechanism of action of HDACi 
(SAHA) targeting of D816V mutated HMC-1.2 mast cells.  
We treated SM cell line HMC-1.2 with SAHA and performed ChIP-seq, for both 
active (H3K27ac and H3K4me3) and repressive histone marks (H3K27me3), and 
ATAC-seq, to study the nucleosome accessibility. We also investigated the HDACi 
mediated effects on the transcriptome by performing RNA-seq, in order to pinpoint 
the mechanism of action of HDACi in SM. 
SAHA treatment induced global transcriptional and chromatin alterations on mutated 
mast cells. The repressive chromatin mark was however not significantly changed on 
a global level, but both the active marks were significantly decreased globally upon 
SAHA treatment. When assessing the global effects on the transcriptome, gene 
ontology analysis revealed that many strongly downregulated genes were in the 
downstream signaling cascade of KIT. There were only modest global effects 
observed on the nucleosome positioning after treatment. 
We moved on to investigate changes in the promoter region of KIT and a region up 
to 1000 kb upstream of the KIT gene. The active mark H3K27ac had a significant 
decrease in the KIT promoter region upon SAHA treatment. The repressive mark 
and the other active mark didn’t demonstrate profound changes. ATAC-seq did not 
demonstrate significant changes on the nucleosome positioning in the KIT promoter 
region. 
In our quest to understand the upstream regulatory network of KIT promoter region 
we overlapped our ChIP-seq data from H3K27ac with the enhancer defined ChIP-
seq data from the FANTOM5 project. We then performed transcription binding site 
(motif) analysis for the peaks/regions that had an exact overlap between the two 
datasets. This resulted in identifying six transcription factors (TAL1, MZF-1, NFIC, 
NR2F2, ZNF24 and ZNF354C) that had a decreased gene expression level after 
SAHA treatment. When analyzing the nucleosome accessibility pattern in the 
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promoter region of these six transcription factors, TAL1 was significantly altered 
upon SAHA treatment. 
Since TAL1 is part of the TAL1/SCL complex we assessed the effect on this 
complex, by analyzing the transcription levels of the different components of the 
complex. GATA1 and TAL1 were significantly decreased on transcript levels already 
after 6 hours of treatment. HDAC1 has been demonstrated in several studies to be 
part of this complex. Altogether our findings indicate a direct targeting of SAHA on 
the TAL1/SCL complex, and we are currently studying the dynamics and 
composition of this complex before and after HDACi treatment.  
In conclusion, we speculate that the mechanism of SAHA mediated killing of D816V 
mutated mast cells occurs partly via targeting HDAC1 which further affects TAL1 
binding in the TAL1/SCL complex. 
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5 CONCLUDING REMARKS AND FUTURE PERSPECTIVES 
 
The advances in the technical field have lead to increased insight to the molecular 
landscapes of several myeloid malignancies. Identification of mutations that are 
leading to development of a myeloid malignancy, as well as which mutations are 
drivers, is important both for finding optimal treatment strategies and giving right 
diagnosis and care in the clinic. The overall goal is to improve the quality of life and 
increase survival of these patients. Despite the increased knowledge in the 
mutational landscape of the different myeloid malignancies discussed in this thesis, 
the current treatment strategies have little overall effect and cure rate. A reason 
behind this is partly due to the heterogeneity of the disease population, and the 
lack of understanding of the exact mechanism of action of the current drugs used 
in the clinic.  
 
In this thesis, epigenetic modulators have been studied in order to mechanistically 
investigate their effect on the epigenome of mutated cells in myeloid malignancies. 
Understanding the effects of these epigenetic modifiers is important in optimizing 
the treatment strategies, as well as development of novel targeted therapies.  
 
Combinatorial treatment strategies of HMA and HDACi have been studied in 
several clinical trials (Griffiths and Gore 2013, Stahl, Gore et al. 2016, Ball, Zeidan 
et al. 2017) with little beneficial results. A key parameter that is lacking in order to 
better optimize the treatment strategies is how to best combine the drugs, and how 
are they interacting with each other. Preclinical studies are therefore important to 
understand the combinatorial effects, and how they interact on molecular level.  
Another issue that requires further knowledge is the optimal drug for a specific 
patient population regarding selectivity and inhibition of clonal and mutated 
proteins, and the pattern of patient specific mutations and chromosomal 
alterations.  
 
There is a lack of a good readout method with the current therapeutic strategies 
that would give information about how the drugs are interacting, and how effective 
they are in different patient populations. This would help in characterizing which 
patient population, with regards to mutational landscape and chromosomal 
aberrations, would benefit from a specific drug.  
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Our studies have contributed with knowledge of how the epigenetic modifiers act to 
modulate the epigenetic landscape in different myeloid malignancies. We found 
profound changes on the epigenetic landscape, however not always corresponding 
to changes on the transcriptome. This emphasizes the complexity in the epigenetic 
machinery, with different factors that either promote or counteract each other. 
Hence, gaining better understanding of how the different drugs modulate the 
epigenetic landscape in the different malignancies provides important knowledge in 
designing future biomarkers to monitor the therapeutic response and obtain 
beneficial clinical outcome. 
 
For future studies in the field of epigenetic modifying drugs, it is important to 
choose the right method to measure the effects on the epigenome. Since the 
sensitivity, coverage, the amount of required biological material, and the 
bioinformatic data processing differ immensely between them, and can affect the 
interpretation of the data.   
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6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Produktionen av olika blodkroppar sker genom det hematopoetiska systemet som 
regleras via flera interna och externa signaler. Den hematopoetiska stamcellen 
(HSC) som finns i benmärgen är ursprungscellen för alla blodkroppar, och kan via 
självförnyelse och multipotenta förmåga generera olika blodkroppar med olika 
funktioner. Det genereras nästan 12 miljoner nya blodkroppar varje sekund från 
denna kompetenta stamcell. När något går fel i denna noggrant reglerade process, 
kan det leda till myeloida maligniteter som MDS, AML och SM, som studeras i denna 
avhandling.  
Denna avhandling ger en mekanistisk inblick i hur de olika läkemedlen som används 
idag för behandling av olika myeloida maligniteter, påverkar arvsmassan. 
De viktigaste fynden är: 
• Vi hittade ett ökat uttryck av immunförsvarsgener, i primära stamceller från 
benmärgen vid behandling av MDS med Azacitidin. 
 
• Vi har visat att histonmodifierande läkemedel kan vara en selektiv, riktad 
behandling vid systemisk mastocytos, en patientgrupp där vi idag saknar bra 
behandling.  
 
• Seleninnehållande läkemedel påverkar leukemiceller epigenetiskt, och leder 
till fästning i benmärgen. Detta skulle kunna fungera som ett komplement till 
befintlig kemoterapi för att bättre komma åt leukemiceller i benmärgen.  
 
Sammanfattningsvis så har vi kunnat påvisa en ökad förståelse för hur olika 
läkemedel påverkar det epigenetiska landskapet i myeloida maligniteter. Detta är en 
viktig kunskap som behövs vid utformningen av framtida biomarkörer för att 
övervaka responsen till behandlingen, samt optimera behandlingsstrategierna så att 
fler patienter gynnas. 
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In Somali: 
Mahad oo dhan waxaa leh Ilaahey subxaana wa tacaala. Qofkaan dadka u mahad 
celin, Alle uma mahad celin (Tirmidhi).  Alle ka kadib waxaan halkan mahad 
balaaran uga jeedinaya inti hiil iyo hooba ila garab taagneed oo waqtigooda qaaliga 
ah igu bixiyay. Qaasatan tageerada buuxda aan ka helay qoyskayga aan jecelahay 
iyo qaraabada dhow, si aan u dhammaystiro PhD-ga. Waxay ii  suurtogaliyeen in 
aan sii wado waxbarashadeyda cilmiga sayniska, la’aantina waa abaar. 
Hooyadaydi aan jeclahay, Seynab, waan kaaga mahad naqayaa wax walba oo aad 
ii samaysay muddada noloshayda oo idil. Guusha caruurtaada ee gaaran ayaa 
farxad weyn ku ah weligaa. Sidaa darteed ayaa dhexda u xiratay hormarka 
caruurtaada in ay ku guuleystaan aduun iyo akhiiroba. Xikmaddaada, deeqsigaga 
iyo jacaylkaaga waa astaan ku dayasho mudan. Waad ku mahadsantahay inta jeer 
aad fasax u qaadatay, si aad u daryeesho caruurtaa ayeeyada u tahay. Waad ku 
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mahadsantahay inta jeer ee la koobin karin aad i dhiirrigelisay, markaan dareemi 
jiray in aysan macquul ahayn oo niyo jab igu dhaco mararka qaar. Waan ku jeclahay 
hooyo macaan, waligay ma ku riyoon hooyo ka wanaagsan adiga. Ilaahey Jannat al- 
firdaws aclaa ha kugu sharfo. Amiin. 
Aabahayga aan jeclahay, Maxamed, jacaylka iyo qadarinta aan ku hayo lama koobi 
karo aabe macaan. Waad ku mahadsantahay dhammaan jacaylka iyo farxadihii aad 
noloshayda ku bixisay, iyo dhiirigelintaada in mar walba cilmiga iyo waxbarashada 
xooga la saaro . Dhamaan dadaalkaaga iyo waqtiga aad ii hurtay hagar la’aan 
barbaarintayda anigu. Rabbi ha kaa abaal mariyo aabe macaan. Ilaahey Jannat al- 
firdaws aclaa ha kugu sharfo.Amiin. 
 
Hooyadaydii labaad aan jecelahay, Qali, sido kale macnaha magacaaga ee 
soomaaliga ayaa tusaale ku ah, waxaad tahay qof qiimo badan ee aan la koobi karin 
abaalka ku qabo. Waxaad tahay qof hami iyo xikmad badan leh iyo qalbi naxariis 
badan. Anigu kuma mahadnaqi karo wax kasta oo aad igu tageerrtay. Waad ku 
mahadsantahay dhamaan hadalkaaga dhiirigelinta ku saleysnaa. Iyo dhammaan 
cuntooyinka macaan ee aad nagu deeqday. Waxaa kale aan koobi karin inta jeer 
adigoo oo shaqo ka soo baxay in aad caruurta ayeeyo u tahay soo martid si aad 
wakhtiga uga faa’iideysto, sida aan shaqadayda u qabsado. Waad ku 
mahadsantahay inaad tahay ”soddohoda” ugu fiican, in kastoo aniga kuu arko 
hooyodayda labaad. Ilaahey Jannat al-firdaws aclaa ha kugu sharfo. Amiin. 
Aabbahayga labaad ee qaaliga eh, Maxamed, waxaa ku mahadsantahay 
taageeradaada iyo dhiirigelintaada aan dhammaadka lahayn. Ilaahey Jannat al-
firdaws aclaa ha kugu sharfo. Amiin. 
Walaalahayga iga yar-yar, Cali, Axmed, Cabdiaziz, Cabdisalam, waad ku 
mahadsantihiin sida mar kasto tageero buuxda ii siisaan marka aan in baahdo. 
Ilaahey ha idin xafido aduun iyo akhiraba. 
Dumaashiyaasheyda, Shukri, Sucaad, Ifraax iyo Ilhaan, waxaad ii gasheen booski 
gabdho ila dhashay camal. Waxaa buuxisin booskii aan ku riyoon jiray runti. Ilaahey 
ha idin xafido dhammantiina. Ma koobi karo inta jeer ee aad iga farxiseen, iyo sida 
hagar la’aanta iyo taageridiina. Ilaahey swt ha idin xafido. Amiin. 
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Cawil, Cabdiraxmaan, Cabdisalaam, Cabdiraxiim, waad ka mahadsantihiin wax 
kasto oo caawimaad aad igu taageerteen. Waxaa tihiin dumaashiyaal aan la iloobi 
karin. Caruurtayda waxay leeyihiin adeero ah kuwa ugu fiican adduunka. Ilaahey ha 
idin xafido. Amiin. 
Xayaat, Mikaiil, Hannah iyo Ca’isha, Ilaahey ayaa mahad leh oo ugu deeqay 
wiilalshayda in ay la dhasheen ilmo abtiyaal ee walaalo yihiin iyo kuwa aan 
aragooda aan ku farxo. Ilaahey ha idin ka dhigo kuwii waalidkooda u baari noqda. 
Amiin. 
Caruurteyda Aadam iyo Ilyaas, Waxaa ii noqoteen farxad Rabbi igu deeqay ee aan 
lo koobi karin, raadka ee ku yeelatay noloshayda. Waxaa tihiin amaana Alle swt igu 
deeqay ee aan indhaha ku qaboowsado. Ilaahey ha idin ka xijaabo xumaan oo 
dhan. Ilaahey ha idin ka yeelo kuwii waalidka dhalay anfaco aduun iyo akhiraba. 
Amiin. 
Seeygeyga Cabdirizaaq, Abaalka kuu qabo lama koobi karo xaqiiqdii. Erayo aan 
kaa qoro kaama turjumi karaan runtii. Waxaa ii tahay qof aan ku tiirsan karo, si 
kastaba ay nolosha inoo qaabisho. Waxaa ila socotay markii aan PHD-ga ku cusbaa 
iyo marxallada aan soo maray. Waxaa tahay qofka kowaad oo tageero iyo dhiirigelin 
ka helo. Intaas waxaa dheer oo ka muhiimsan doorkaaga aabenimada iyo sida aad 
isku xilqaantay. Xilkaaga aabe sida aa u gudatay ayaa markhaati u ah, in aan geliyo 
wakhti shaqada PhD-ga. Waxaa tahay seey iyo aabe caruurtiisa jecel oo naxariis 
badan oo hormarkeena ku dadaalayo. Ilaahey ayaa mahad leh oo qoys inaga 
dhigay. Waan ku jeclahay qalbi u roon. Ilaahey ha ku xafido aduun iyo akhiro. Amiin. 
Ilaahey subxaana wa tacaala ayaa mahad idil u sugnaatay, oo i sahlay nimcooyinka 
la koobi karin igu deeqay.  
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